Development Aspects, Physiochemical Characteristics, Pharmaceutical Requirements and Different Manufacturing Procedures for Dry Powder Inhalation Formulations

Authors

  • Sulabha Sambhaji Lalsare Assistant Professor, Department of Botany, Shri Swami Shatkopacharyaji Maharaj Arts, Science and Commerce College, Saikheda, Ta-Niphad, Dist. Nashik, Maharashtra, India

Keywords:

Dry powder inhaler, DPI, formulation development, particles, physico-chemical properties, drug delivery

Abstract

Dry Powder Inhalation (DPI) products are combination of pharmacologic activity and pharmaceutical properties including procedure used to manufacture. Desirable performance features of DPI are physical and chemical stability, ease of handling, accurate and reproducible delivery to the target organ and availability of drug at the site of action. The physical stability of DPI is of utmost importance as it results in ultimate deposition of drug through various dispersion mechanisms into the lungs from where it acts locally or is absorbed and circulated.  This can be achieved by selecting suitable manufacturing procedure under appropriate environmental conditions. This review focuses on development process, manufacturing techniques and various parameters related to the stability and performance of the DPI formulation. Most DPI formulations consist of micronized drug blended with lactose of different particle size as carrier, which enhances flow, reduce aggregation and aid in dispersion. The intrinsic physical and chemical properties, particle size, form, shape, surface area, and morphology affects the forces involved in interaction and aerodynamic behaviour, which in turn determine fluidization, dispersion, distribution of drug to the lungs and deposition in the airways. When a DPI is actuated, the formulation is fluidized and enters the lungs. Inspiratory airflow separates drug particles from the carrier particles and are carried deep into the peripheral airways, while the larger carrier particles impact on the oropharyngeal surfaces and are cleared. If the shear of the airflow is not sufficient to separate the drug from the carrier particles due to strong cohesive forces acting on the powder and may results in low deposition efficiency. The force of adsorption of drug on carrier particles determines the percentage of drug deposition in the lungs.

References

Telko MJ, Hickey AJ. Dry Powder Inhaler Formulation. Respir Care. 2005; 50(9): 1209–27p.

Maghsoudi S, Taghavi Shahraki B, et al. The Colorful World of Carotenoids: A Profound Insight on Therapeutics and Recent Trends in Nano Delivery Systems. Crit Rev Food Sci Nutr. 2021; 1–40p.

Lavorini F. The Challenge of Delivering Therapeutic Aerosols to Asthma Patients. Int Sch Res Notices. 2013; 2013: 102418p.

Verma RK, Garg S. Drug Delivery Technologies and Future Directions. Pharma Technol. 2001; 25(2): 1–4p.

Yurdasiper A, Arıcı M, Ozyazici M. Nanopharmaceuticals: Application in Inhaler Systems. Emerging Nanotechnologies in Immunology. Elsevier; 2018; 165–201p.

Zhang X. The Development of a Noval Dry Powder Inhaler. Int J Pharma. 2012; 431(1–2): 45–52p.

Weers JG, Bell J, et al. Pulmonary Formulations: What Remains to be Done? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010; 23(Suppl 2): S-5–23p.

Naik S, Mukherjee R, Chaudhuri B. Triboelectrification: A Review of Experimental and Mechanistic Modeling Approaches with a Special Focus on Pharmaceutical Powders. Int J Pharm. 2016; 510(1): 375–85p.

Telko MJ. Investigation of Electrostatic Charging Phenomena in Dry Powder Inhalers and the Effect on Deposition. University Library; Mar 21, 2019. [online] Available from: https://cdr.lib.unc.edu/concern/dissertations/9w032362g

Abuzar SM, Hyun SM, et al. Enhancing the Solubility and Bioavailability of Poorly Water-Soluble Drugs Using Supercritical Antisolvent (SAS) Process. Int J Pharm. 2018; 538(1–2): 1–3p.

Weiss C, McLoughlin P, Cathcart H. Characterisation of Dry Powder Inhaler Formulations Using Atomic Force Microscopy. Int J Pharm. Oct 15, 2015; 494(1): 393–407p. 12. Tse JY, Kadota K, Imakubo T, Uchiyama H, Tozuka Y. Enhancement of the Extra-Fine Particle Fraction of Levofloxacin Embedded in Excipient Matrix Formulations for Dry Powder Inhaler Using Response Surface Methodology. Eur J Pharm Sci. 2021; 156: 105600p.

Baklanov A, Sørensen JH. Parameterisation of Radio Nuclide Deposition in Atmospheric Long-Range Transport Modelling. Physics and Chemistry of the Earth, Part B: Hydrology, Oceans and Atmosphere. 2001; 26(10): 787–99p.

Cyrys J, Stölzel M, Heinrich J, et al. Elemental Composition and Sources of Fine and Ultrafine Ambient Particles in Erfurt, Germany. Sci Total Environ. 2003; 305(1–3): 143–56p.

Pilcer G, Wauthoz N, Amighi K. Lactose Characteristics and the Generation of the Aerosol. Adv Drug Deliv Rev. Mar 15, 2012; 64(3): 233–56p.

Jain H, Bairagi A, Srivastava S, Singh SB, Mehra NK. Recent Advances in the Development of Microparticles for Pulmonary Administration. Drug Discov Today. 2020; S1359-6446(20)30298-1.

Kubavat HA. The Influence of Crystallisation on the Mechanical and Interfacial Properties of Active Pharmaceutical Ingredients. Doctoral Dissertation. University of Bath; Jun 1, 2019. [Online] Available from: https://researchportal.bath.ac.uk/en/studentTheses/the-influence-of-crystallisation-on-the-mechanical-and-interfacia. 18. Meiring JJ. Ausdem Institut für umweltmedizinische Forschung (IUF) an der Heinrich-Heine-Universität Düsseldorf.

Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle Engineering for Pulmonary Drug Delivery. Pharm Res. 2007; 24(3): 411–37p.

Pilcer G, Amighi K. Formulation Strategy and Use of Excipients in Pulmonary Drug Delivery. Int J Pharm. 2010; 392(1–2): 1–9p.

Nokhodchi A, Martin GP, editors. Pulmonary Drug Delivery: Advances and Challenges. Wiley; 2015.

Downloads

Published

2021-06-16

Issue

Vol. 8 No. 1 (2021)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.